Publications by authors named "Fatos Onen"

CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile. The aim of this study was to evaluate the long-term drug persistence, safety, and efficacy of infliximab biosimilar CT-P13 in patients with AS undergoing first-line (1st-line) and later (≥2nd-line) treatment in clinical practice.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the retention rates and remission outcomes of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who started treatment with secukinumab over 24 and 48 months.
  • Data was collected from 13 European registries, revealing that retention rates were around 51%-64%, and patients with no prior biologic treatments showed better outcomes compared to those with previous treatments.
  • The findings suggest that secukinumab remains effective over four years, with higher success rates in treatment-naïve patients compared to those who had already tried other therapies.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore gender differences in the phenotypical expression of Behçet's disease (BD) using data from the International AIDA Network Registry, focusing on damage index, disease manifestations, and cardiovascular risk.
  • A total of 1024 patients (567 males and 457 females) were examined, revealing that males had a significantly higher overall damage index and more frequent occurrences of uveitis and vascular involvement, while females showed higher instances of arthralgia, arthritis, and CNS involvement.
  • Key factors associated with major organ involvement included male gender, treatment with biologic agents, origin from endemic regions, and longer disease duration, indicating a more severe course of BD in males compared to females.
View Article and Find Full Text PDF

Objectives: Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians' awareness.

View Article and Find Full Text PDF

Objectives: To investigate sex differences in patient-reported outcome measures (PROMs) among axSpA patients initiating their first TNFi and identify factors contributing to these disparities over the follow-up.

Methods: Data were included from 15 EuroSpA registries and consisted of axSpA patients initiating their first TNFi, with ≥2 measurements for each analysed PROM (BASDAI and BASFI, scale 0-100) taken at any time point. Linear mixed models were employed to analyse sex differences in PROMs over 24 months and to evaluate how baseline characteristics were related to the observed sex differences.

View Article and Find Full Text PDF

Objectives: This study aims to investigate the effect of age on disease activity and biological treatment in patients with ankylosing spondylitis (AS).

Patients And Methods: A total of 811 AS patients registered in the TURKBIO registry database between 2011 and 2019 were categorized according to their age at the time of entry into the registry and assigned to one of two groups: young patients, defined as <60 years of age (n=610), and those aged ≥60 years (n=201) were recorded as elderly patients. Demographic, clinical, and laboratory characteristics, along with disease activity markers and other follow-up parameters, as well as current and prior treatments, were electronically recorded during each visit using open-source software.

View Article and Find Full Text PDF

Clinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset.

View Article and Find Full Text PDF

Background/aim: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the antirheumatic agents in inflammatory diseases. The aim of the study was to determine whether the body mass index (BMI) is involved in the response to rituximab in rheumatoid arthritis (RA).

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of two common immunosuppressive agents, methotrexate (MTX) and azathioprine (AZA), as first-line treatments for patients with Takayasu's arteritis (TAK), analyzing patient outcomes and safety.
  • A total of 301 TAK patients from 10 centers were included; findings revealed similar remission and relapse rates between MTX and AZA, but a significantly higher rate of vascular surgery in the AZA group compared to MTX.
  • The study also noted that patients on MTX were more likely to receive lower doses of glucocorticoids post-treatment compared to those on AZA, indicating different management outcomes between the
View Article and Find Full Text PDF
Article Synopsis
  • The study looked at patients with PsA (psoriatic arthritis) who started a 2nd or 3rd TNFi (a type of medicine) and how many continued taking it after a year.
  • Out of the patients studied, about 68% stayed on their 2nd TNFi and 66% on their 3rd TNFi after a year.
  • The results showed that effectiveness of the new medicine depended on why they stopped taking the previous one, with better outcomes for those who stopped because the first medicine didn’t work as well after some time.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the occurrence of spondyloarthritis (SpA) features in 350 patients with Takayasu arteritis (TAK), finding that 8.8% had additional SpA-related conditions, such as inflammatory bowel disease (IBD) or psoriasis.
  • - Patients with both TAK and SpA displayed earlier onset of disease symptoms and required more aggressive biological treatments for active vasculitis compared to those with TAK alone.
  • - The research highlighted the overlap between TAK and SpA, suggesting a potential link in their pathogenesis, possibly related to an MHC class I allele similar to that seen in spondyloarthritis.
View Article and Find Full Text PDF
Article Synopsis
  • A study examined cancer rates in patients with ANCA-associated vasculitis (AAV) by comparing them to cancer risks in the Turkish population and identifying independent risk factors.
  • Of the 461 AAV patients tracked, 19 developed cancer after an average follow-up of about 3.4 years, with higher cancer risks noted in older males and those with anti-PR3-ANCA positivity.
  • The overall cancer risk for AAV patients was 2.1 times higher than that of the general population, highlighting the need for targeted cancer screening, especially for lung and head-neck cancers in older male patients.
View Article and Find Full Text PDF

Background: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi).

Methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline.

View Article and Find Full Text PDF
Article Synopsis
  • * Researchers analyzed data from 330 patients diagnosed with GCA, finding that 18.8% experienced relapses during a follow-up period, and only 23.8% were able to stop GC treatment entirely.
  • * The study highlighted that a significant portion of patients (66.2%) had at least one indication of damage due to vasculitis, and there were also considerable side effects related to GC treatment.
View Article and Find Full Text PDF

Objective: This study aimed to measure the functional exercise capacity of patients with ankylosing spondylitis (AS) with the incremental shuttle walk test (ISWT), and to determine the factors associated with this test.

Methods: This cross-sectional study included 54 patients with AS (29 males, 25 females). The ISWT was performed to determine functional exercise capacity.

View Article and Find Full Text PDF

Objective: To determine the rate of unintentional monotherapy (UM; switching to monotherapy from combination therapy of patients' own volition) in rheumatoid arthritis patients receiving tofacitinib and to evaluate tofacitinib survival rate.

Methods: This national, multicenter study included patients' data from the TURKBIO Registry. Demographics, clinical characteristics, disease duration and activity, comorbidities, and treatments were analyzed.

View Article and Find Full Text PDF

In routine rheumatology practice, we noticed that a significant number of male ankylosing spondylitis (AS) patients did not experience inflammatory back pain (IBP). Based on this observation, we aimed to investigate the prevalence of IBP in male AS patients and compare it to that in female patients. Patients with AS who fulfilled the modified New York criteria were subjected to a face-to-face interview with a standardized questionnaire that addressed the IBP components based on the Berlin criteria.

View Article and Find Full Text PDF

Background: Inflammatory skin diseases (ISDs), are characterized by dysregulated activation of innate and adaptive immune systems, with inflammatory cytokines playing a crucial role in their pathogenesis.

Objectives: This study aimed to investigate the involvement of Janus kinase/signal transduction and activator of transcription (JAK/STAT) signaling pathway in the pathogenesis of ISDs.

Methods: The study analyzed a total of 117 skin biopsies, comprising 31 from pyoderma gangrenosum (PG), 25 from hidradenitis suppurativa (HS), 35 from psoriasis patients, and 26 from control subjects.

View Article and Find Full Text PDF

Introduction: We aimed to investigate the effects of the coronavirus disease 2019 (COVID-19) pandemic on the course and treatment of patients with inflammatory rheumatic musculoskeletal disease (iRMD) using biologic or targeted synthetic disease modifying and rheumatic drugs (b/tsDMARDs).

Methodology: The study was carried out in two stages: in the first stage we investigated the delay of b/tsDMARD treatment in the first 3 months of the pandemic; in the second stage, we investigated all patients who decided to continue treatment after interruption in the 12-month period.

Results: A total of 521 patients were included in the study.

View Article and Find Full Text PDF

Introduction: This paper describes the creation and preliminary results of a patient-driven registry for the collection of patient-reported outcomes (PROs) and patient-reported experiences (PREs) in Behçet's disease (BD).

Methods: The project was coordinated by the University of Siena and the Italian patient advocacy organization SIMBA (Associazione Italiana Sindrome e Malattia di Behçet), in the context of the AIDA (AutoInflammatory Diseases Alliance) Network programme. Quality of life, fatigue, socioeconomic impact of the disease and therapeutic adherence were selected as core domains to include in the registry.

View Article and Find Full Text PDF

Objectives: The aim of this study was to evaluate the impact of obesity on the treatment response to secukinumab and drug survival rate in patients with ankylosing spondylitis (AS).

Methods: We performed an observational cohort study that included AS patients based on the biological drug database in Turkey (TURKBIO) Registry between 2018 and 2021. The patients were divided into three groups: normal [body mass index (BMI) < 25 kg/m2], overweight (BMI: 25-30 kg/m2), and obese (BMI ≥ 30 kg/m2).

View Article and Find Full Text PDF

Objective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis.

View Article and Find Full Text PDF